Mitochondrial and peroxisomal fatty acid beta-oxidation machinery (FAO machinery) (FAO machinery)

The mitochondrial and peroxisomal fatty acid beta-oxidation (FAO) machinery is a multi-enzymatic system essential for the catabolism of fatty acids to generate energy. Mitochondrial FAO is the major source of ATP during fasting or prolonged exercise, processing short- to long-chain fatty acids through a four-step cycle of dehydrogenation, hydration, oxidation, and thiolysis (Source: StatPearls, NBK556002). Peroxisomal FAO specializes in the initial shortening of very-long-chain fatty acids (VLCFAs) and branched-chain fatty acids before they are transferred to mitochondria for complete oxidation (Source: UniProt, Q15067). Dysregulation of these pathways is linked to various metabolic disorders, including inherited fatty acid oxidation deficiencies like MCAD deficiency and acquired conditions like non-alcoholic fatty liver disease (Source: NIH, Genetic and Rare Diseases Information Center). Pharmacological modulation of this machinery, such as through CPT1 inhibitors like etomoxir or PPAR-alpha agonists like fibrates, is used to treat angina and dyslipidemia by shifting metabolic substrates or increasing lipid clearance (Source: PubMed, PMID: 25660364). However, therapeutic targeting requires careful balance to avoid systemic toxicity, such as non-ketotic hypoglycemia or hepatic steatosis, resulting from impaired energy homeostasis (Source: PubMed, PMID: 11375334).

Other names

Fatty acid beta-oxidation pathwayFAO systemMitochondrial fatty acid oxidationPeroxisomal fatty acid oxidation

Drugs targeting this machinery typically act by inhibiting key rate-limiting enzymes like Carnitine Palmitoyltransferase 1 (CPT1) to shift metabolism from fatty acids to glucose, or by activating nuclear receptors like PPAR-alpha to upregulate the expression of beta-oxidation enzymes (Source: PubMed, PMID: 15591007; StatPearls, NBK559219).